Discontinuation of Oral Anticoagulation After Successful Atrial Fibrillation Ablation – Are We Ready to Change Clinical Practice in 2026?

Introduction

Atrial fibrillation (AF) is a common cardiac arrhythmia with an incidence that substantially increases according to age [1]. This incidence is expected to continue rising, with projections indicating that the prevalence will reach 15.9 million in the United States by 2050 and 17.9 million in Europe by 2060 [2,3]. AF may lead to serious cardiac and systemic complications, making it a serious public health concern [4]. Moreover, patients with AF have a fivefold higher risk of stroke than the general population [5]. Currently, oral anticoagulation (OAC) is used to mitigate stroke risk in these patients. The decision to initiate OAC is based on clinical risk-stratification tools, such as the CHA2DS2-VA score (standardized in Europe via the 2024 European Society of Cardiology [ESC] guidelines) or the CHA2DS2-VASc score (currently used in the United States and previously applied in Europe). Other models, including the GARFIELD or ATRIA scores, may serve as adjunctive tools [6,7].

Catheter ablation (CA) is an established AF treatment method [6]. It allows maintenance of sinus rhythm over an extended period and reduces the risks of heart failure and ischemic stroke [8,9]. The gold standard for AF ablation is pulmonary vein isolation, which is most commonly achieved using radiofrequency energy, cryoablation, or pulsed-field ablation [10]. Pulmonary vein isolation remains the cornerstone of the procedure, but adjunctive substrate-modification strategies (eg, posterior wall isolation, linear lesions, or ablation of low-voltage zones) are frequently utilized to target extrapulmonary triggers. Although data from randomized trials have been mixed, recent large-scale meta-analyses suggest that these additional interventions can greatly improve long-term rhythm control, particularly in patients with persistent AF [11,12]. Moreover, CA has been shown to reduce AF burden by up to 99% [13], using a definition of AF burden as cumulative exposure to AF over time; this burden is correlated with the risk of ischemic stroke [14,15]. The recurrence rate of AF after CA currently varies according to pulmonary vein isolation method, AF type, and patient characteristics [16]. A substantial proportion of patients remain free of AF and consistently maintain sinus rhythm long after CA; however, a meta-analysis indicated that 50.6% of patients maintained freedom from any AF recurrence at 5 years after the procedure [17].

These observations raise the question of whether anticoagulant use is justified and beneficial in patients who maintain sinus rhythm after successful CA, given the potential adverse effects, including bleeding risk. The incidence of major bleeding events among patients with AF receiving OAC is approximately 2% to 4% per year [18]. Another question is whether successful ablation reduces stroke risk to a level that allows cessation of anticoagulation.

Recently, 2 prospective randomized trials addressing this issue have been published [19,20]. In the present review, we compare these new data, discuss them in the context of current guidelines and existing literature, and identify potential directions for future research.

Evidence Prior to Randomized Controlled Trials

Before the advent of prospective randomized trials evaluating long-term anticoagulation strategies following successful ablation of AF, clinical decisions were almost exclusively based on expert consensus and observational data (eg, cohort studies, registries, and meta-analyses of noninterventional studies). Consequently, guidelines were inherently conservative. Guidelines from the ESC and the American Heart Association (AHA)/American College of Cardiology (ACC)/Heart Rhythm Society (HRS) emphasize the need to continue OAC during the periprocedural and immediate post-ablation period (at least 2 months according to the ESC and at least 3 months according to the AHA/ACC/HRS), with the subsequent decision based on stroke risk (assessed using the CHA2DS2-VA/CHA2DS2-VASc scores) rather than the perceived efficacy of the procedure or the maintenance of sinus rhythm [6,7]. Earlier consensus documents (eg, the HRS/European Heart Rhythm Association [EHRA]/European Cardiac Arrhythmia Society [ECAS] position paper on AF ablation) reinforced this principle: OAC after ablation should be continued for a minimum of 2 months; subsequent discontinuation should be considered cautiously and based on the patient’s thromboembolic risk profile, rather than documented rhythm control alone [21].

The key argument for this approach was an evidence gap, namely the lack of randomized trials sufficiently robust to minimize patient-selection effects and observational bias in addressing whether OAC can be safely discontinued after successful ablation, particularly among patients with at least moderate stroke risk. In clinical practice, there has been (and still is) a strong impulse to de-escalate treatment for patients who maintain sinus rhythm. This tendency is understandable because chronic anticoagulation involves a measurable bleeding risk, treatment-related discomfort, and financial cost. However, data from the pre-randomized controlled trial (RCT) era consistently indicated that the risk of stroke after ablation is not solely determined by the presence of overt arrhythmia recurrences but largely reflects the underlying biological substrate (atrial disease, age, comorbidities, and vascular risk factors). This reasoning was reinforced by experience from earlier studies comparing rhythm-control and rate-control strategies in AF (pre-ablation era), which identified paradoxical thromboembolic events after OAC had been discontinued due to sinus rhythm. Historically, these observations acted as a restraint on liberal discontinuation of anticoagulation solely related to rhythm control [6,7,21].

Observational data after ablation, however, presented a mixed picture. Numerous cohort studies showed a low stroke rate among carefully selected patients in whom OAC was discontinued after a “successful” procedure, especially those with low CHA2DS2-VA/CHA2DS2-VASc scores. Those studies also highlighted a recurring problem: in real-world practice, OAC is sometimes discontinued even in high-risk patients, often contrary to recommendations. A representative example is the analysis from the German Ablation Registry, which demonstrated that OAC is frequently discontinued after ablation of paroxysmal AF, even among patients with a history of stroke, and that thromboembolic events occurred substantially more often in this high-risk group. The authors explicitly argued against discontinuation of OAC after ablation in patients with prior stroke [22]. Such observations had a direct impact on clinical practice, reinforcing a “safety-first” approach and a conservative interpretation of risk, which in many centers translated into routine continuation of OAC among patients with CHA2DS2-VASc scores of 2 or greater, regardless of the subjective impression of arrhythmia resolution.

Meta-analyses from the pre-RCT era attempted to resolve these conflicting signals, but the quality of the input data limited their conclusions. A meta-analysis by Proietti et al indicated that the risk-benefit balance may favor suspension of OAC after successful ablation, even among patients with moderate to high risk. However, the authors emphasized uncertainty regarding the generalizability of their results, particularly given variability in treatment and monitoring strategies and the inherent limitations of observational data [23]. Similarly, a meta-analysis by Liu et al suggested the potential for safe discontinuation of OAC after successful ablation, with a concomitant signal of increased bleeding among patients who continued OAC. However, the authors clearly emphasized heterogeneity among studies and the need for large randomized trials to confirm their findings [24]. A more recent meta-analysis by Wang et al indicated that discontinuation of OAC could reduce the risk of major bleeding without a substantial increase in thromboembolic events. Nevertheless, the results were affected by limitations typical of cohort-based meta-analyses, including patient selection bias (OAC more often discontinued in healthier patients), variability in the definition of ablation “success,” and inconsistent rhythm monitoring [25]. In summary, meta-analyses from the pre-RCT era often concluded that discontinuation appears safe in selected patients but failed to address a fundamental issue: they did not clearly identify which patients, and under what monitoring standards, discontinuation can be considered safe.

An additional layer of uncertainty arose from the fact that “no recurrence” in observational studies was often defined based on symptoms, occasional electrocardiogram recordings, or short-term Holter monitoring. Such surveillance can miss asymptomatic or short-lived arrhythmias and thus tends to underestimate the true burden of AF. This methodological weakness led to practical consequences: clinicians had no reliable means to distinguish a patient with truly minimal AF exposure from a patient with undetected recurrence – in whom discontinuation of OAC might be unsafe. Consequently, in the absence of randomized data and given uncertainty regarding the quality of rhythm surveillance, guidelines and clinical practice both tended to favor continued OAC in patients with substantial risk of stroke.

In recent years, before publication of the RCTs, large contemporary registry analyses also emerged, further demonstrating that post-ablation risk is not uniform and that the simple designation of “successful ablation” is an oversimplification. The work by Kanaoka et al showed in registry data that the benefits and risks of continuing OAC after ablation vary according to patient profile; the authors noted that discontinuation of OAC may increase stroke risk, particularly among high-risk patients [26]. Subsequently, the analysis by Iwawaki et al – still observational but methodologically important – demonstrated a typical trade-off: discontinuation of OAC after “successful” ablation was associated with reduced bleeding but also with a higher number of thromboembolic events, and this effect varied according to patient characteristics [27]. These findings reinforced the conclusion that – without randomization and in the absence of more precise patient phenotyping and standardized monitoring – it was not possible to safely recommend an OAC discontinuation strategy for a broad population after ablation.

In summary, the pre-RCT era left clinicians in a state of controlled uncertainty. There was a consistent message that in low-risk patients with a stable clinical profile, discontinuation of OAC could be reasonable and might reduce bleeding risk. However, real-world data showed that discontinuation was also performed in high-risk populations (eg, patients with prior stroke) and could have serious adverse consequences [22]. Meta-analyses suggested a potential net benefit of discontinuation but did not resolve key limitations, including selection bias, heterogeneity, inconsistent success definitions, and imperfect rhythm monitoring [23–25]. This evidence gap directly affected clinical management: guidelines maintained the paradigm of assessing stroke risk without considering rhythm status, whereas clinical practice – due to concerns about catastrophic stroke outcomes in the event of inappropriate de-escalation – often favored continued OAC in patients with increased risk [6,7]. It was precisely this discrepancy between clinical intuition (sinus rhythm implies lower risk) and the limited reliability of observational data (and possibility of silent AF) that created the rationale for randomized trials. Controlled studies with clearly defined populations and endpoints were required to determine whether, and in whom, chronic anticoagulation could be safely discontinued after successful ablation.

Data From Prospective Randomized Controlled Trials

The year 2025 brought the first prospective randomized controlled data addressing the safety of discontinuing OAC therapy after successful AF ablation. Two trials, ALONE-AF [19] and OCEAN [20], provide early evidence regarding thromboembolic risk and bleeding outcomes in this setting.

Although these studies appear methodologically comparable at first glance, critical differences summarized in Table 1 require careful analysis before clinical conclusions can be drawn. First, the pharmacologic regimens in the control arms substantially differed: OCEAN used rivaroxaban at a reduced dose of 15 mg daily, whereas ALONE-AF used standard dosing of either apixaban (5 mg twice daily) or rivaroxaban (20 mg once daily). Furthermore, the intervention arms represent distinct clinical strategies. In OCEAN, anticoagulation was replaced with aspirin (70–120 mg) among all patients assigned to this arm, regardless of whether they had independent indications for antiplatelet therapy. In contrast, ALONE-AF evaluated discontinuation of OAC. As stated in the trial methodology, antiplatelet therapy was generally discouraged to allow assessment of a truly antithrombotic-free strategy; however, it remained permissible for specific clinical indications, such as percutaneous coronary intervention or acute coronary syndrome. Consequently, 8.6% of patients in the intervention group received antiplatelet agents. A comparison of baseline clinical and demographic characteristics between the 2 cohorts is presented in Table 2.

Key differences also exist concerning efficacy surveillance and exposure duration. OCEAN incorporated mandatory baseline and 3-year brain magnetic resonance imaging (MRI) for all participants, thereby substantially increasing sensitivity for detection of covert embolic strokes. Finally, the follow-up duration differed between the trials: 3 years in OCEAN and 2 years in ALONE-AF. These methodological differences in drug dosing, comparator selection, and diagnostic monitoring suggest that each trial captures distinct aspects of post-ablation risk. Primary and secondary endpoint outcomes (eg, incidence of thromboembolic events and bleeding complications across the study arms) are summarized in Table 3.

In early 2026, a comprehensive meta-analysis was published that synthesized data from 32 studies, including the aforementioned RCTs, encompassing 271 808 patients [28]. The analysis revealed no significant differences in thromboembolic events or all-cause mortality between groups. Notably, discontinuation of OAC was associated with a significantly lower incidence of major bleeding events (odds ratio 0.35, P<0.01). However, in a subgroup analysis of patients with a CHA2DS2-VASc score greater than 2, OAC cessation was linked to a significantly higher thromboembolic risk; potential mechanisms underlying this observation are discussed below.

Discussion

WHEN IS IT SAFE TO STOP?:

From a pathophysiologic perspective, the immediate postprocedural period constitutes a transient but critical high-risk window that mandates uninterrupted protection. CA inevitably induces pronounced iatrogenic injury. Delivery of thermal energy results in widespread endothelial denudation and exposure of the subendothelial matrix, which acts as a potent substrate for platelet aggregation and thrombus formation [29–32]. Furthermore, the procedure triggers a systemic inflammatory response and local “ablation cascade” that activates prothrombotic factors [33]. Along with injury to the atrial wall, the mechanical function of the left atrium (LA) is often impaired [34].

In contrast, pulsed field ablation exhibits a distinct pathophysiologic profile. This approach has been shown to induce lower levels of inflammation and reduced platelet activation relative to conventional thermal energy sources, suggesting a mechanism more conducive to short-term endothelial preservation; however, it is simultaneously associated with substantially higher markers of myocardial injury compared with radiofrequency ablation [35]. Consequently, regardless of the energy source used, these mechanisms temporarily create a paradoxically prothrombotic environment, warranting OAC for at least 2 to 3 months to bridge the vulnerable phase of tissue healing and endothelial recovery [6,7].

Notably, due to the timing of their recruitment periods, both the ALONE-AF and OCEAN trials excluded patients undergoing pulsed field ablation. Consequently, the long-term thromboembolic risk profile specific to this modality remains uncharacterized. Given the rapid clinical adoption of pulsed field ablation, the findings of these RCTs may lack contemporary applicability for a substantial portion of patients.

Beyond this obligatory blanking period, the optimal timing for discontinuation remains undefined. The OCEAN and ALONE-AF trials both required a conservative 1-year waiting period after ablation prior to randomization. This rigorous 12-month inclusion criterion raises a fundamental clinical question: is such a prolonged duration necessary to confirm stability of sinus rhythm? Registry data and Kaplan-Meier analyses consistently demonstrate that ablation efficacy progressively declines over time, but the distinction between early responders and nonresponders often becomes evident much sooner. Thus, confirmation of stability at an earlier time point (eg, 6 months) might be sufficient to identify patients eligible for discontinuation, potentially sparing them an additional half year of unnecessary bleeding exposure associated with the prolonged waiting period used in these trials.

WHEN IS IT TOO RISKY TO QUIT?:

A considerable gap in current evidence concerns patients with high thromboembolic risk. The mean CHA2DS2-VASc scores in ALONE-AF and OCEAN were 2.1±1.0 and 2.2±1.1, respectively. Consequently, patients with high thromboembolic risk were greatly underrepresented in these cohorts. Designing an RCT to test discontinuation of anticoagulation in this subgroup may be extremely difficult. At present, withdrawal of anticoagulation in such patients appears ethically problematic; randomized data for this vulnerable population may never become available. Accordingly, clinicians will likely need to rely on observational and retrospective studies, which inherently lack the robustness of RCT evidence.

Future risk stratification for thromboembolic complications will likely move beyond reliance on static clinical scores toward a more comprehensive characterization of the prothrombotic substrate. Maintenance of sinus rhythm after a successful ablation procedure does not necessarily guarantee normalization of the thromboembolic milieu, particularly if the underlying atrial myopathy – manifested by impaired strain mechanics, reduced LA emptying fraction, or abnormal left atrial appendage flow dynamics – persists.

Advanced imaging using speckle-tracking echocardiography enables detection of LA dysfunction by quantifying LA strain parameters, which provide a direct measure of myocardial deformation and mechanical function [36]. Khan et al reported that LA contractile strain measured 3 months after ablation was an independent predictor of AF recurrence [37]. Notably, in fewer than half of patients with persistent AF, mechanical atrial recovery – defined as positive global atrial strain of 21% or greater – occurred within 3 months after electrical cardioversion [38]. Impaired LA strain after rhythm-control interventions may be associated with suboptimal mechanical recovery and potentially increased thromboembolic risk [39]. Therefore, incorporation of LA functional parameters assessed via speckle-tracking echocardiography into post-CA risk stratification may complement structural imaging and clinical scores, leading to more personalized anticoagulation decision-making.

Evidence also suggests that increased LA volume and reduced LA reservoir function are independently associated with subclinical cerebrovascular disease detected by brain MRI, even among individuals without a history of stroke [40]. Furthermore, detection of LA fibrosis by delayed-enhancement MRI is independently associated with prior stroke and may serve as an important marker of future events [41]. Recent data further support this substrate-driven risk, showing that markers such as elevated N-terminal pro-brain natriuretic peptide (NT-proBNP; >250 pg/mL) or severe LA enlargement are significantly associated with higher National Institutes of Health Stroke Scale (NIHSS) scores and worse prognosis in acute ischemic stroke populations, regardless of rhythm status [42]. Moreover, in a retrospective cohort study by Iwawaki et al, discontinuation of OAC was associated with a significantly higher thromboembolic risk, particularly among patients with LA diameter above 45 mm, left ventricular ejection fraction below 60%, or a history of asymptomatic AF [27].

The CHA2DS2-VASc score may also fail to capture the prothrombotic risk associated with systemic inflammation. Among individuals with known AF, the stroke rate in those exhibiting rheumatoid arthritis or systemic lupus erythematosus is higher than can be explained by conventional clinical scores [43,44]. This elevated rate likely reflects the fact that the score does not incorporate measures of systemic inflammation or direct assessments of atrial myopathy; consequently, some authors have proposed adjusting the CHA2DS2-VASc score for patients with systemic inflammatory disorders [45]. The danger of a purely rhythm-centric approach was previously observed in clinical trials where the rhythm-control group paradoxically experienced a higher risk of thromboembolic events [46]. This higher risk was likely driven by discontinuation of OAC according to the mistaken assumption that AF itself, rather than the underlying atrial myopathy, was the primary driver of stroke.

Moreover, local thromboembolic risk is continuously modulated by dynamic systemic factors, including glycemic control and blood pressure variability, which require long-term optimization beyond the acute procedural period. The complexity of these interacting variables will likely require integration of artificial-intelligence-based models, which are already used in cardiology to manage multidimensional data and improve risk prediction. An important long-term clinical dilemma persists: if a patient remains free of AF recurrence but, after several years, develops a high-risk profile due to aging or new comorbidities, should anticoagulation be reinitiated despite the absence of documented arrhythmia?

HOW NOT TO MISS RECURRENCE:

Selection of a monitoring strategy involves a necessary trade-off among invasiveness, cost, and diagnostic yield, as detailed in Table 4. Although consumer wearables offer accessibility, recent data caution against their premature adoption for safety-critical decision-making. Results from the SMART-ALERT study highlighted serious reliability gaps. In a direct comparison, implantable cardiac monitors integrated with automated software achieved a 74% success rate in delivering alerts for AF episodes lasting longer than 30 minutes, whereas the Apple Watch and CART Ring notified participants of only 19.5% and 15.1% of episodes, respectively. This substantial performance difference was primarily driven by suboptimal device adherence; the Apple Watch missed 24.6%, while the CART Ring missed 55.7%, of AF episodes simply because the devices were not being worn. Additionally, technical limitations of intermittent photoplethysmography introduced detection bias against shorter arrhythmias, such that wearables detected fewer than 10% of episodes lasting 1 to 3 hours, compared with more than 60% of episodes exceeding 24 hours [47]. Recognizing these technological limitations, the recently initiated RESPOND-AF study aims to evaluate a real-world “pill-in-the-pocket” pathway guided by automated alerts from implantable cardiac monitors, addressing the reliability gap identified in wearable-based protocols [NCT06922695].

This technology-driven approach is particularly relevant for the post-ablation population. Given that post-ablation arrhythmia recurrences are often infrequent and exhibit a short duration, as demonstrated in the DISCERN-AF study [48], the concept of dynamic, episode-triggered anticoagulation warrants rigorous validation as an alternative to lifelong therapy in this specific cohort. The need for continuous rhythm monitoring becomes evident when considering the limitations of both OCEAN and ALONE-AF, which primarily relied on intermittent Holter monitoring to verify sinus rhythm. Intermittent monitoring provides only a fragmented snapshot of the post-ablation period. In real-world practice, absence of symptoms is a poor surrogate for absence of arrhythmia. The disconnect between symptoms and AF burden is well documented; notably, the DISCERN-AF study demonstrated that the ratio of asymptomatic to symptomatic episodes increased more than threefold after ablation, and 12% of patients experienced exclusively asymptomatic recurrences [48]. Consequently, reliance on intermittent monitoring likely underestimates the true incidence of subclinical recurrences, which carry a stroke risk comparable to that of symptomatic episodes, as clearly demonstrated in the ASSERT trial [49].

HOW TO REACT TO THE RECURRENCE:

A promising therapeutic evolution enabled by enhanced monitoring is the “pill-in-the-pocket” anticoagulation strategy. The general feasibility of this approach is supported by a meta-analysis of 711 patients using daily rhythm monitoring, which showed a low annualized ischemic stroke rate of 0.5% together with a significant reduction in anticoagulant use [50]. To definitively test this hypothesis, the ongoing REACT-AF trial [NCT05836987] has been designed as a multicenter, prospective, randomized, open-label study with blinded endpoint assessment. It compares the current standard of care – continuous OAC use – with a time-delimited strategy (1 month of anticoagulation) guided by an AF-sensing smartwatch. The study aims to provide definitive evidence concerning whether consumer wearables can safely guide on-demand anticoagulation therapy over a 3- to 5-year follow-up period. Supporting the rationale for this trial, a recent patient-level computational simulation of the REACT-AF protocol predicted that such an on-demand strategy would be noninferior to continuous anticoagulation for prevention of stroke and mortality (P=0.88) while significantly reducing major bleeding events (P=0.011) [51].

However, adoption of continuous rhythm assessment introduces a complex set of clinical dilemmas regarding therapeutic response. The superior sensitivity of these devices inevitably leads to detection of subclinical, short-duration episodes, creating a critical decision point: does such a finding mandate permanent resumption of systemic anticoagulation, or is a time-limited, episode-triggered approach sufficient to mitigate risk? This diagnostic precision also requires re-evaluation of interventional strategies, specifically whether repeat ablation should be pursued not only for symptom control but also primarily to restore an “OAC-free” status. This concept is supported by the OCEAN trial, in which nearly one-quarter of participants needed multiple ablation procedures to achieve the sinus rhythm stability required for enrollment.

Consequently, before dynamic anticoagulation can be established as a standard of care, robust clinical algorithms must be developed that integrate recurrence density, burden thresholds, and reintervention strategies.

Conclusions

The ALONE-AF and OCEAN trials provide the first randomized evidence supporting the feasibility of OAC discontinuation among selected low- to moderate-risk patients without documented AF recurrence. However, these findings require cautious interpretation due to underrepresentation of high-risk cohorts, the absence of continuous rhythm monitoring that can detect subclinical paroxysmal events, and the persistent prothrombotic influence of the underlying atrial substrate.